Syndax Pharmaceuticals (SNDX) Competitors $10.67 -0.23 (-2.11%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNDX vs. CYTK, SRPT, KRYS, ACAD, SWTX, ZLAB, RARE, ACLX, ALVO, and PTGXShould you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Cytokinetics (CYTK), Sarepta Therapeutics (SRPT), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE), Arcellx (ACLX), Alvotech (ALVO), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Syndax Pharmaceuticals vs. Its Competitors Cytokinetics Sarepta Therapeutics Krystal Biotech ACADIA Pharmaceuticals SpringWorks Therapeutics Zai Lab Ultragenyx Pharmaceutical Arcellx Alvotech Protagonist Therapeutics Cytokinetics (NASDAQ:CYTK) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and institutional ownership. Is CYTK or SNDX more profitable? Syndax Pharmaceuticals has a net margin of 0.00% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cytokinetics-17,906.25% N/A -50.21% Syndax Pharmaceuticals N/A -64.34%-57.72% Does the MarketBeat Community prefer CYTK or SNDX? Cytokinetics received 439 more outperform votes than Syndax Pharmaceuticals when rated by MarketBeat users. Likewise, 79.83% of users gave Cytokinetics an outperform vote while only 65.22% of users gave Syndax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCytokineticsOutperform Votes83179.83% Underperform Votes21020.17% Syndax PharmaceuticalsOutperform Votes39265.22% Underperform Votes20934.78% Which has better earnings and valuation, CYTK or SNDX? Syndax Pharmaceuticals has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$19.22M206.32-$526.24M-$5.29-6.28Syndax Pharmaceuticals$43.72M21.00-$209.36M-$3.86-2.76 Does the media prefer CYTK or SNDX? In the previous week, Cytokinetics had 13 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 18 mentions for Cytokinetics and 5 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.33 beat Cytokinetics' score of 0.35 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, CYTK or SNDX? Cytokinetics has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Do analysts recommend CYTK or SNDX? Cytokinetics currently has a consensus price target of $70.92, suggesting a potential upside of 113.62%. Syndax Pharmaceuticals has a consensus price target of $35.91, suggesting a potential upside of 236.54%. Given Syndax Pharmaceuticals' higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Cytokinetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.93Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 SummaryCytokinetics and Syndax Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNDX vs. The Competition Export to ExcelMetricSyndax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$918.12M$6.94B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-2.948.7927.2619.97Price / Sales21.00263.06412.06157.64Price / CashN/A65.8538.2534.64Price / Book1.636.597.064.69Net Income-$209.36M$144.20M$3.24B$248.14M7 Day Performance-4.39%3.81%2.56%2.39%1 Month Performance-2.91%11.10%8.75%6.06%1 Year Performance-47.36%3.95%31.30%13.57% Syndax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNDXSyndax Pharmaceuticals3.012 of 5 stars$10.67-2.1%$35.91+236.5%-43.6%$918.12M$43.72M-2.94110Positive NewsCYTKCytokinetics4.4184 of 5 stars$31.21+0.6%$73.71+136.2%-37.9%$3.73B$19.22M-5.80250Analyst ForecastAnalyst RevisionSRPTSarepta Therapeutics4.831 of 5 stars$37.74+0.4%$122.61+224.9%-68.8%$3.71B$2.23B30.19840KRYSKrystal Biotech4.695 of 5 stars$125.36-0.5%$211.13+68.4%-21.3%$3.62B$333.45M41.93210Positive NewsAnalyst RevisionACADACADIA Pharmaceuticals3.2497 of 5 stars$21.47-0.5%$26.83+25.0%+48.4%$3.59B$996.28M27.53510SWTXSpringWorks Therapeutics1.5909 of 5 stars$46.67-0.1%$52.57+12.6%+20.1%$3.52B$219.67M-13.41230Positive NewsHigh Trading VolumeZLABZai Lab1.4694 of 5 stars$31.19+3.5%$47.37+51.9%+106.6%$3.44B$418.33M-11.261,950Positive NewsAnalyst RevisionGap UpRAREUltragenyx Pharmaceutical4.4194 of 5 stars$36.14+6.2%$88.77+145.6%-9.4%$3.42B$590.69M-5.701,310Analyst RevisionACLXArcellx2.8058 of 5 stars$61.93-0.2%$111.33+79.8%+22.5%$3.41B$76.81M-87.2280Insider TradeAnalyst RevisionALVOAlvotech1.7035 of 5 stars$11.22-1.9%$18.00+60.4%-29.7%$3.38B$585.60M-6.064Short Interest ↑PTGXProtagonist Therapeutics2.0116 of 5 stars$50.15+5.6%$65.44+30.5%+63.0%$3.11B$207.80M18.85120Insider Trade Related Companies and Tools Related Companies CYTK Alternatives SRPT Alternatives KRYS Alternatives ACAD Alternatives SWTX Alternatives ZLAB Alternatives RARE Alternatives ACLX Alternatives ALVO Alternatives PTGX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNDX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNDX Stock Free SNDX Stock Alerts